Selective Expansion of Regulatory T-Cells in Humans by a Novel IL-2 Conjugate T-reg Stimulator, NKTR-358, Being Developed for the Treatment of Autoimmune Diseases

C. Fanton, S. Siddhanti, N. Dixit, L. Lu, T. Gordi, D. Dickerson, J. Zalevsky, B. Kotzin
Disclosures

• C. Fanton, S. Siddhanti, N. Dixit, L. Lu, T. Gordi, J. Zalevsky, B. Kotzin are employees of Nektar Therapeutics and own shares of the company

• D. Dickerson is an employee of PRA Healthsciences
IL-2 is Critical for Treg Expansion, Function and Control of Immune Responses by Tregs

Many autoimmune disorders, including SLE, are associated with:

- Reduced Treg numbers
- Impaired Treg function
- Reduced systemic IL-2
NKTR-358: PEG-conjugated rhIL-2 Selectively Induces Regulatory T-cells (Tregs) and Their Suppressive Activity

PEG-conjugation:
• Alters binding profile of NKTR-358 (vs IL-2) with lower binding affinity to IL-2Rβ and different binding bias for IL-2Rα & IL-2Rβ
• Imparts selectivity for effect on Tregs over Tcons (vs IL-2)
• Increases half life (vs IL-2)

NKTR-358 has shown activity in animal models of SLE and cutaneous hypersensitivity
NKTR-358: Single Ascending Dose Study Objectives

Assess the effects of subcutaneous administration of single-ascending doses of NKTR-358 in healthy volunteers on:

**Primary**

- Safety and tolerability in subjects as evaluated by:
  - Adverse events
  - Vital signs
  - Clinical laboratory
  - Cytokine levels

**Secondary**

- Time course and extent of changes in the numbers and activity of Tregs, Tcons, and NK cells and subsets
- Pharmacokinetics (PK) of NKTR-358
- Other immunological effects: cytokine levels, peripheral blood cell populations, serum proteins and gene expression
**Study Design: Randomized Double-blind Study of Subcutaneous Single Ascending Doses of NKTR-358 in Healthy Volunteers**

Healthy Volunteers (N=100)
Age: 18 – 54 yrs.
Males: 60%
Females: 40%

Each cohort followed for 50 days

<table>
<thead>
<tr>
<th>Cohort</th>
<th>NKTR-358 Dose</th>
<th>Placebo</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.3 µg/kg</td>
<td></td>
<td>(n=9)</td>
</tr>
<tr>
<td>2</td>
<td>1.0 µg/kg</td>
<td></td>
<td>(n=9)</td>
</tr>
<tr>
<td>3</td>
<td>3.0 µg/kg</td>
<td></td>
<td>(n=9)</td>
</tr>
<tr>
<td>4</td>
<td>6.0 µg/kg</td>
<td></td>
<td>(n=9)</td>
</tr>
<tr>
<td>5</td>
<td>9.0 µg/kg</td>
<td></td>
<td>(n=9)</td>
</tr>
<tr>
<td>6</td>
<td>13.5 µg/kg</td>
<td></td>
<td>(n=9)</td>
</tr>
<tr>
<td>7</td>
<td>20.0 µg/kg</td>
<td></td>
<td>(n=13)</td>
</tr>
<tr>
<td>8</td>
<td>28.0 µg/kg</td>
<td></td>
<td>(n=3)</td>
</tr>
</tbody>
</table>

Study Enrolled and Follow-up Complete
NKTR-358 SAD Study Results: NKTR-358 was Safe and Well Tolerated in Healthy Volunteers

- No dose-limiting toxicities, deaths, or AEs leading to study discontinuation
- No clinically significant vital sign, ECG, or physical examination abnormalities
- Adverse events primarily limited to mild or moderate (Grade 1 or 2) injection site reactions
- 4 subjects experienced Grade 1 mild events of headache
- 1 subject at the highest dose tested (28.0 µg/kg) experienced mild (Grade 1) signs and symptoms of vomiting, diarrhea, anorexia, tachycardia, and myalgia attributed to elevated cytokine levels
- No anti-drug antibodies detected
NKTR-358 Concentration Curves Indicate Dose Proportional Pharmacokinetics*

- NKTR-358 Cmax and AUC values exhibited a dose proportional increase
- NKTR-358 concentrations reached maximum levels in 4-6 days
- NKTR-358 has an estimated elimination half-life of 8-9 days

*PK analyses preliminary and in progress
NKTR-358 Leads to Sustained, Dose-dependent Increases in CD25\textsuperscript{bright} Tregs

- At 28 µg/kg NKTR-358:
  - 17-fold mean peak increase in numbers of CD25\textsuperscript{bright} Tregs above predose value
  - Treg levels peak at Days 10-12 and do not return to baseline until Days 20-25 following administration
- Increase in Treg activation markers ICOS and CTLA4 were observed at doses >13.5 µg/kg
NKTR-358: No Changes in Numbers of Tcon Cells and Low-level Increases in Numbers of CD56+ NK Cells

Mean fold change of CD4+ cells

Mean fold change of CD8+ cells

Mean fold change of CD56+ NK cells

Day of administration

Not all cohorts are shown for clarity
NKTR-358 SAD Study: Conclusions

• Safe and well tolerated in this first in human study
• Preliminary data suggest dose proportional pharmacokinetics and prolonged exposure with a half-life of 8-9 days
• Marked and selective dose-dependent expansion of CD25^{bright} Treg cells
• No measurable changes in numbers and percentages of CD4+ and CD8+ Tcons at all doses and low-level increases of NK cell numbers at highest doses tested
• Data provide strong support for studying NKTR-358 in autoimmune and inflammatory diseases
• NKTR-358 is currently being studied in a multiple ascending dose clinical trial in patients with SLE and additional studies in other inflammatory diseases are planned